Point72 Asia (Singapore) Pte. Ltd. Aadi Bioscience, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $532 Billion
- Q3 2024
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Aadi Bioscience, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 12,121 shares of AADI stock, worth $36,241. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,121
Previous 25,176
51.85%
Holding current value
$36,241
Previous $36.8 Million
32.07%
% of portfolio
0.0%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding AADI
# of Institutions
55Shares Held
12.6MCall Options Held
23.8KPut Options Held
0-
Avoro Capital Advisors LLC New York, NY2.85MShares$8.52 Million0.09% of portfolio
-
Bml Capital Management, LLC Zionsville, IN2MShares$5.98 Million2.42% of portfolio
-
Acuta Capital Partners, LLC Belmont, CA1.85MShares$5.53 Million3.86% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA1.85MShares$5.52 Million0.16% of portfolio
-
Vanguard Group Inc Valley Forge, PA766KShares$2.29 Million0.0% of portfolio
About Aadi Bioscience, Inc.
- Ticker AADI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 21,016,800
- Market Cap $62.8M
- Description
- Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...